Results from the LITESPARK-015 open-label, multicohort phase 2 trial show that hypoxia-inducible factor-2 alpha inhibitor belzutifan achieves durable antitumor activity…
Biomarkers and Clonal Dynamics Group
Results of a VHIO led study show that up to 90% of chronically hypoxic patients have an EPAS1 alteration in…
Liquid biopsy is increasingly stepping up as a non-invasive approach in detecting and tracking circulating tumor DNA (ctDNA) in blood…
